Previous work has showed that siRNA treatment of Angptl3 reduced the proteinuria and hypertriglyceridemia in a rat model with puromycin-induced NS, indicating that ANGPLT3 is a potential target for podocytopathy [6, 7]. This evidence concerns the gene ANGPTL3 and hypertriglyceridemia.